#

About us

Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd. Driven by innovation and development...

Huaota focuses on the research and development of new biological drugs in the fields of tumor...
More

NEWS

18
2023-10
Article Publication | Huaota HB0017 (IL-17A Monoclonal Antibody) Phase I Clinical Study Published
Abstract:Recently, Dr. Yongmin Yang, Vice...
Learn more+
12
2023-10
China’s first CD73-targeting antibody cocktail HB0045 has been administered to its first patient in the United States
SUMMARYShanghai Huaota Biopharmaceutical ...
Learn more+
12
2023-10
Huaota will present promising result of HB0034 at the 32nd EADV
The much-anticipated 32nd EUROPEAN ACADEM...
Learn more+

Product pipeline

More

TALENT
RECRUITMENT

More

Contact us

Contact number:

+86-021-51320756
  • Contact Us

    Investor Relations：IR@huaota.com

    Business Cooperation：Huaota_BD@huaota.com

    Human Resources：hr@huaota.com

    Quality Feedback：zlfk@huaota.com

    Compliance Reporting：hgjb@huaota.com

  • Transfer to drug vigilance

    If you discover any suspected adverse events related to Hua'ao Tai products, please contact us through the following channels:

    Drug Vigilance Hotline：+86-021-51213273

    Drug Vigilance Email：pvhuaota@huaota.com